User profiles for N. Sheron

Nick Sheron

Visiting Professor, Institute of Hepatology, Kings College, London
Verified email at kcl.ac.uk
Cited by 13466

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri… - The Lancet, 2022 - thelancet.com
Liver diseases have become a major health threat across Europe, and the face of European
hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral …

Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries

R Moodie, D Stuckler, C Monteiro, N Sheron, B Neal… - The lancet, 2013 - thelancet.com
… In the global north—ie, North America and Europe—ultra-processed products have largely
replaced food systems and dietary patterns based on fresh and minimally processed food …

Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of …

…, J O'Grady, R Pryke, H Rutter, S Ryder, N Sheron… - The Lancet, 2014 - thelancet.com
Liver disease in the UK stands out as the one glaring exception to the vast improvements
made during the past 30 years in health and life expectancy for chronic disorders such as …

Priority actions for the non-communicable disease crisis

…, J Ralston, M Rani, KS Reddy, F Sassi, N Sheron… - The lancet, 2011 - thelancet.com
The UN High-Level Meeting on Non-Communicable Diseases (NCDs) in September, 2011,
is an unprecedented opportunity to create a sustained global movement against premature …

Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies

…, E Corbould, JV Lazarus, L Webber, N Sheron… - Journal of …, 2018 - Elsevier
The burden of liver disease in Europe continues to grow. We aimed to describe the epidemiology
of liver diseases and their risk factors in European countries, identifying public health …

Guidelines on the management of abnormal liver blood tests

…, A Mackie, R Mitchell-Thain, K Sennett, NC Sheron… - Gut, 2018 - gut.bmj.com
These updated guidelines on the management of abnormal liver blood tests have been
commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society …

Increased plasma tumor necrosis factor in severe alcoholic hepatitis

GLA Bird, N Sheron, AKJ Goka… - Annals of internal …, 1990 - acpjournals.org
Study Objective: To determine whether elevated tumor necrosis factor levels contribute to
the clinical manifestations and complications of severe acute alcoholic hepatitis and to …

[PDF][PDF] Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study

…, N Sheron, M Wright, N Curzen… - …, 2014 - Wiley Online Library
… activity during the study (available in n 582 of 91 participants). In … membrane n-3 PUFA
enrichment independent of n-6 PUFA … Prolonged n-3 polyunsaturated fatty acid supplementation …

Hepatic changes in the failing Fontan circulation

CH Kiesewetter, N Sheron, JJ Vettukattill, N Hacking… - Heart, 2007 - heart.bmj.com
Background: The failing Fontan circulation is associated with hepatic impairment. The nature
of this liver injury is poorly defined. Objective: To establish the gross and histological liver …

Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease

…, R Payne, P Johnson, N Sheron - The Journal of …, 2003 - Wiley Online Library
Mucosal changes in inflammatory bowel disease (IBD) are characterized by ulcerative
lesions accompanied by prominent cellular infiltrates in the bowel wall. Chemokines are …